Effectiveness of metformin on weight loss in non-diabetic individuals with obesity

Experimental and Clinical Endocrinology and Diabetes

Volumn 121, Issue 1, 2013, Pages 27-31

  Seifarth, C ^a   Schehler, B ^a   Schneider, H J ^b  

^a Practice for Endocrinology   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

insulin resistance; metformin; obesity

Indexed keywords

GLUCOSE; INSULIN; METFORMIN;

ADULT; ARTICLE; BLOATING; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OUTPATIENT CARE; PATIENT MONITORING; PRIORITY JOURNAL; STOMACH PAIN; TREATMENT DURATION; WEIGHT REDUCTION;

ADULT; AGE FACTORS; BODY MASS INDEX; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; OBESITY; OUTPATIENTS; SEX FACTORS; TIME FACTORS; WEIGHT LOSS;

EID: 84872617193     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0032-1327734     Document Type: Article

References (50)

1. Li Z., Maglione M., Tu W. et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med: 2005; 142 532 546
2. Christopoulou F. D., Kiortsis D. N. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. J Clin Pharm Ther: 2011; 36 10 18
3. Meneghini L. F., Orozco-Beltran D., Khunti K. et al. Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab: 2011; 96 3337 3353
4. Bennett W. L., Odelola O. A., Wilson L. M. et al. Evaluation of guideline recommendations on oral medications for type 2 diabetes mellitus: a systematic review. Ann Intern Med: 2012; 156 27 36
5. Sterne J. Pharmacology and mode of action of hypoglycaemic guanidine derivatives. In: Campbell G. D. (ed.). Oral hypoglycaemic agents. London Academic: 1969; 193 245
6. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev: 1997; 18 774 800 (Pubitemid 28009567)
7. Unlühizarci K., Keleştimur F., Bayram F. et al. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol: 1999; 51 231 236 (Pubitemid 29378909)
8. Lee A., Morley J. E. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res: 1998; 6 47 53 (Pubitemid 128679644)
9. Stumvoll M., Nurjhan N., Perriello G. et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med: 1995; 333 550 554
10. Lustig R. H. Hypothalamic obesity: the sixth cranial endocrinopathy. The Endocrinologist: 2002; 12 210 217 (Pubitemid 34602855)
11. Sigal R. J., El-Hashimy M., Martin B. C. et al. Acute post-challenge hyperinsulinemia predicts weight gain. Diabetes: 1997; 46 1025 1029 (Pubitemid 27221004)
12. Odeleye O. E., de Courten M., Pettitt D. J. et al. Fasting hyperinsulinemia is a predictor of increased body weight gain and obesity in Pima Indian children. Diabetes: 1997; 46 1341 1345 (Pubitemid 27315284)
13. Bailey D. J., Turner R. C. Metformin. N Engl J Med: 1996; 334 574 579 (Pubitemid 126537875)
14. Hermann L. S., Melander A. Biguanides: basic aspects and clinical uses. In: Alberti KGM M., DeFronzo R. A., Keen H., Zimmet P. (eds.). International textbook of diabetes mellitus. Vol. 1 Chichester, England John Wiley: 1992; 773 795
15. Knowler W. C., Barrett-Connor E., Fowler S. E. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med: 2002; 346 393 403 (Pubitemid 34437694)
16. Diabetes Prevention Program Research Group Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care: 2012; 35 731 772
17. Fontbonne A., Diouf I., Baccara-Dinet M. et al. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial. Diabetes Metab: 2009; 35 385 391
18. Gambineri A., Patton L., Vaccina A. et al. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome. J Clin Endocrinol Metab: 2006; 91 3970 3980 (Pubitemid 44536872)
19. Derosa G., Maffioli P. Anti-obesity drugs: a review about their effects and their safety. Expert Opin Drug Saf: 2012; 11 459 471
20. Ara R., Blake L., Gray L. et al. What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review. Health Technol Assess: 2012; 1 1 195
21. Bray G. A., Ryan D. H. Medical Therapy for the Patient with Obesity. Circulation: 2012; 125 1695 1703
22. Gillies C. L., Abrams K. R., Lambert P. C. et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ: 2007; 334 299 308
23. Setter S. M., Iltz J. L., Thams J. et al. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther: 2003; 25 2991 3026 (Pubitemid 38096142)
24. Haffner S., Temprosa M., Crandall J. et al. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes: 2005; 54 1566 1572
25. Wang M., Tong J. H., Zhu G. et al. Metformin for treatment of antipsychotic-induced weight gain: A randomized, placebo-controlled study. Schizophr Res: 2012; 138 54 57
26. Bushe C. J., Bradley A. J., Doshi S. et al. Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies. Int J Clin Pract: 2009; 63 1743 1761
27. Park M. H., Kinra S., Ward K. J. et al. Metformin for obesity in children and adolescents: a systematic review. Diabetes Care: 2009; 32 1743 1745
28. Mauras N., DelGiorno C., Hossain J. et al. Metformin use in children with obesity and normal glucose tolerance-effects on cardiovascular markers and intrahepatic fat. J Pediatr Endocrinol Metab: 2012; 25 33 40
29. Metwally M., Amer S., Li T. C. et al. of metformin versus orlistat for the management of obese anovulatory women. Hum Reprod: 2009; 24 966 975
30. Harborne L. R., Sattar N., Norman J. E. et al. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab: 2005; 90 4593 4598 (Pubitemid 41159348)
31. Ghandi S., Aflatoonian A., Tabibnejad N. et al. The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study. J Assist Reprod Genet: 2011; 28 591 596
32. Matsuda M., DeFronzo R. A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care: 1999; 22 1462 1470 (Pubitemid 29418240)
33. Levri K. M., Slaymaker E., Last A. et al. Metformin as treatment for overweight and obese adults: a systematic review. Ann Fam Med: 2005; 3 457 461 (Pubitemid 41512664)
34. Goodpaster B. H., Kelley D. E., Wing R. R. et al. Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes: 1999; 48 839 847 (Pubitemid 29153085)
35. Glueck C. J., Fontaine R. N., Wang P. et al. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism: 2001; 50 856 861 (Pubitemid 32700469)
36. Gokcel A., Gumurdulu Y., Karakose H. et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab: 2002; 4 49 55 (Pubitemid 34285267)
37. Mogul H. R., Peterson S. J., Weinstein B. I. et al. Long-term (2-4 year) weight reduction with metformin plus carbohydrate-modified diet in euglycemic, hyperinsulinemic, midlife women (Syndrome W). Heart Dis: 2003; 5 384 392 (Pubitemid 37521683)
38. Dohm G. L., Tapscott E., Pories W. et al. An in vitro human muscle preparation suitable for metabolic studies. Decreased insulin stimulation of glucose transport in muscle from morbidly obese and diabetic subjects. J Clin Invest: 1988; 82 486 494
39. Oppert J. M., Nadeau A., Tremblay A. et al. Plasma glucose, insulin, and glucagon before and after long-term overfeeding in identical twins. Metabolism: 1995; 44 96 105
40. Luyckx A. S., Lefevbre P. J. Plasma insulin in reactive hypoglycemia. Diabetes: 1971; 20 435 442
41. Schultes B., Oltmanns K. M., Kern W. et al. Modulation of hunger by plasma glucose and metformin. J Clin Endocrinol Metab: 2003; 88 1133 1141 (Pubitemid 36337767)
42. Giannarelli R., Aragona M., Coppelli A. et al. Reducing insulin resistance with metformin: the evidence today. Diabetes Metab: 2003; 29 28 35
43. Mizuno T. M., Funabashi T., Kleopoulos S. P. et al. Specific preservation of biosynthetic responses to insulin in adipose tissue may contribute to hyperleptinemia in insulin-resistant obese mice. J Nutr: 2004; 134 1045 1050 (Pubitemid 38619937)
44. Cusin I., Terrettaz J., Rohner-Jeanrenaud F. et al. Hyperinsulinemia increases the amount of GLUT4 mRNA in white adipose tissue and decreases that of muscles: a clue for increased fat depot and insulin resistance. Endocrinology: 1990; 127 3246 3248
45. Tan S., Hahn S., Benson S. et al. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol: 2007; 157 669 676 (Pubitemid 350187385)
46. Paolisso G., Amato L., Eccellente R. et al. Effect of metformin on food intake in obese subjects. Eur J Clin Invest: 1998; 28 441 446 (Pubitemid 28326408)
47. Mick G. J., Wang X., Ling Fu C. et al. Inhibition of leptin secretion by insulin and metformin in cultured rat adipose tissue. Biochim Biophys Acta: 2000; 1502 426 432
48. Morin-Papunen L. C., Koivunen R. M., Tomas C. et al. Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab: 1998; 83 2566 2568 (Pubitemid 28503063)
49. Mannucci E., Ognibene A., Cemasco F. et al. Effect of metformin on glucagon-like peptide-1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care: 2001; 24 489 494 (Pubitemid 32198418)
50. Mannucci E., Tesi F., Bardini G. et al. Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes. Diabetes Nutr Metab: 2004; 17 336 342